MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner

Blood

Volumn 121, Issue 23, 2013, Pages 4617-4626

  Shindo, Takero ^a   Kon Kim, Tae ^a   Benjamin, Cara L ^a   Wieder, Eric D ^a   Levy, Robert B ^b   Komanduri, Krishna V ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; SELUMETINIB; TACROLIMUS; BENZIMIDAZOLE DERIVATIVE; CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SELECTIVITY; EPSTEIN BARR VIRUS; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SHORT COURSE THERAPY; T LYMPHOCYTE; ALLOTRANSPLANTATION; ANIMAL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL CULTURE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG ANTAGONISM; DRUG EFFECT; EPSTEIN BARR VIRUS INFECTION; FLOW CYTOMETRY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; PATHOGENICITY; PATHOLOGY; PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TRANSPLANTATION TOLERANCE; VIROLOGY; WESTERN BLOTTING;

ANIMALS; BENZIMIDAZOLES; BLOTTING, WESTERN; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EPSTEIN-BARR VIRUS INFECTIONS; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC MEMORY; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PHOSPHORYLATION; RATS; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

MLCS; MLOWN;

EID: 84881077536     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-476218     Document Type: Article

References (47)

1. Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer. 2004;101(9):1936-1946.
2. Ferrara JL, Reddy P. Pathophysiology of graftversus-host disease. Semin Hematol. 2006;43(1): 3-10.
3. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285(5426):412-415.
4. Sprent J, Schaefer M, Lo D, Korngold R. Properties of purified T cell subsets. II. In vivo responses to class I vs. class II H-2 differences. J Exp Med. 1986;163(4):998-1011.
5. Locatelli F, Percivalle E, Comoli P, et al. Human cytomegalovirus (HCMV) infection in paediatric patients given allogeneic bone marrow transplantation: role of early antiviral treatment for HCMV antigenaemia on patients' outcome. Br J Haematol. 1994;88(1):64-71.
6. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003; 9(9):543-558.
7. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754): 708-712.
8. Champagne P, Ogg GS, King AS, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature. 2001;410(6824):106-111.
9. Chen BJ, Cui X, Sempowski GD, Liu C, Chao NJ. Transfer of allogeneic CD62L-memory T cells without graft-versus-host disease. Blood. 2004; 103(4):1534-1541.
10. Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG. Host-reactive CD81 memory stem cells in graftversus-host disease. Nat Med. 2005;11(12): 1299-1305.
11. Anderson BE, McNiff J, Yan J, et al. Memory CD41 T cells do not induce graft-versus-host disease. J Clin Invest. 2003;112(1):101-108.
12. Zheng H, Matte-Martone C, Jain D, McNiff J, Shlomchik WD. Central memory CD81 T cells induce graft-versus-host disease and mediate graft-versus-leukemia. J Immunol. 2009;182(10): 5938-5948.
13. Zheng H, Matte-Martone C, Li H, et al. Effector memory CD41 T cells mediate graft-versusleukemia without inducing graft-versus-host disease. Blood. 2008;111(4):2476-2484.
14. Chen BJ, Deoliveira D, Cui X, et al. Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. Blood. 2007;109(7):3115-3123.
15. Gamadia LE, Rentenaar RJ, Baars PA, et al. Differentiation of cytomegalovirus-specific CD8(1) T cells in healthy and immunosuppressed virus carriers. Blood. 2001;98(3):754-761.
16. Cobb MH, Goldsmith EJ. How MAP kinases are regulated. J Biol Chem. 1995;270(25): 14843-14846.
17. Lu SX, Alpdogan O, Lin J, et al. STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease. Blood. 2008;112(13):5254-5258.
18. Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007;13(5):1576-1583.
19. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-2146.
20. Falchook GS, Lewis KD, Infante JR, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(8):782-789.
21. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367(18):1694-1703.
22. Flaherty KT, Robert C, Hersey P, et al; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107-114.
23. Komanduri KV, Viswanathan MN, Wieder ED, et al. Restoration of cytomegalovirus-specific CD41 T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med. 1998; 4(8):953-956.
24. Komanduri KV, Feinberg J, Hutchins RK, et al. Loss of cytomegalovirus-specific CD41 T cell responses in human immunodeficiency virus type 1-infected patients with high CD41 T cell counts and recurrent retinitis. J Infect Dis. 2001;183(8): 1285-1289.
25. Ozdemir E, St John LS, Gillespie G, et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD81 T cells. Blood. 2002;100(10):3690-3697.
26. Kim TK, St John LS, Wieder ED, Khalili J, Ma Q, Komanduri KV. Human late memory CD81 T cells have a distinct cytokine signature characterized by CC chemokine production without IL-2 production. J Immunol. 2009;183(10): 6167-6174.
27. Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a novel inhibitor of mitogenactivated protein kinase kinase. J Biol Chem. 1998;273(29):18623-18632.
28. Banerji U, Camidge DR, Verheul HM, et al. The first-in-human study of the hydrogen sulfate (Hydsulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res. 2010;16(5):1613-1623.
29. Bekaii-Saab T, Phelps MA, Li X, et al. Multiinstitutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011;29(17):2357-2363.
30. Gaucher D, Therrien R, Kettaf N, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med. 2008;205(13):3119-3131.
31. Precopio ML, Betts MR, Parrino J, et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8 (1) T cell responses. J Exp Med. 2007;204(6): 1405-1416.
32. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD81 T cells. Blood. 2006;107(12):4781-4789.
33. Haass NK, Sproesser K, Nguyen TK, et al. The mitogen-activated protein/extracellular signalregulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res. 2008; 14(1):230-239.
34. Martins SL, St John LS, Champlin RE, et al. Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood. 2004;104(12):3429-3436.
35. Wherry EJ, Ha SJ, Kaech SM, et al. Molecular signature of CD81 T cell exhaustion during chronic viral infection. Immunity. 2007;27(4): 670-684.
36. Kersh EN, Kaech SM, Onami TM, et al. TCR signal transduction in antigen-specific memory CD8 T cells. J Immunol. 2003;170(11):5455-5463.
37. Zhang W, Konopleva M, Burks JK, et al. Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim. Cancer Res. 2010;70(6): 2424-2434.
38. Pei XY, Dai Y, Youssefian LE, et al. Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. Blood. 2011; 118(19):5189-5200.
39. KiesslingMK, Oberholzer PA,Mondal C, et al. Highthroughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood. 2011;117(8):2433-2440.
40. Bhalla S, Evens AM, Dai B, Prachand S, Gordon LI, Gartenhaus RB. The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. Blood. 2011;118(4):1052-1061.
41. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(1)CD25(1) regulatory T cells suppress lethal acute graftversus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389-399.
42. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(1)CD25(1) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99(10):3493-3499.
43. Edinger M, Hoffmann P, Ermann J, et al. CD41 CD251 regulatory T cells preserve graft-versustumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9(9):1144-1150.
44. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117(3):1061-1070.
45. Luo X, Zhang Q, Liu V, Xia Z, Pothoven KL, Lee C. Cutting edge: TGF-beta-induced expression of Foxp3 in T cells is mediated through inactivation of ERK. J Immunol. 2008;180(5): 2757-2761.
46. Gabryšová L, Christensen JR, Wu X, Kissenpfennig A, Malissen B, O'Garra A. Integrated T-cell receptor and costimulatory signals determine TGF-b-dependent differentiation and maintenance of Foxp31 regulatory T cells. Eur J Immunol. 2011;41(5): 1242-1248.
47. Gilmartin AG, Bleam MR, Groy A, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res. 2011; 17(5):989-1000.